TVTX
Travere Therapeutics, Inc.
$58.36
+0.51 (+0.88%)
At close · Jul 8
Market Cap
$5.43B
Shares
92,992,905
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$490.73M
+110.5%
FY2025
Net Income
-$25.55M
+92.1%
FY2025
Gross Margin
97.89%
+1.2pp
FY2025
Operating Margin
-12.8%
+126.1pp
FY2025
Diluted EPS
-$0.29
+92.9%
FY2025
Operating Cash Flow
$37.78M
+115.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $536.2M | $490.73M | $233.18M | $145.24M | $212.02M | $227.49M | $198.32M | $175.34M | $164.25M | — | — | — | — | — | — | $0 | |
| — | — | — | — | — | — | — | — | $5.5M | — | — | — | — | — | — | — | |
| $7.61M | $10.34M | $7.74M | $11.45M | $7.59M | $6.78M | $6.13M | $5.23M | $5.53M | $3.61M | $4.55M | $2.19M | $570.98K | — | — | — | |
| $528.59M | $480.39M | $225.43M | $133.79M | $204.43M | $220.71M | $192.2M | $170.1M | $158.72M | — | — | — | — | — | — | — | |
| — | 97.89% | 96.68% | 92.12% | 96.42% | 97.02% | 96.91% | 97.01% | 96.63% | — | — | — | — | — | — | — | |
| $216.22M | $206.01M | $217.5M | $244.99M | $7.5M | $210.33M | $131.77M | $140.96M | $123.76M | $78.17M | $70.85M | $50.43M | $47.8M | $7.98M | $877K | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $12.83K | |
| $357.04M | $337.2M | $264.12M | $265.54M | $220.21M | $149.88M | $135.8M | $128.95M | $103.65M | $101.33M | $92.8M | $79.54M | $59.64M | $50.32M | $1.36M | — | |
| $71.61M | $59.21M | $41.74M | $36.28M | $30.96M | $24.95M | $22.44M | $19.71M | $18.03M | $17.33M | $15.99M | $13.23M | — | — | — | — | |
| — | $60.74M | $43.56M | $38.53M | $33.08M | $26.62M | $24.58M | $20.41M | $18.67M | $17.8M | $16.14M | $13.39M | $5.4M | $341.23K | $125.24K | — | |
| — | $0 | $2.44M | $11.39M | — | — | $0 | $0 | -$242K | $3.61M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $244.29M | $208.73M | $191.81M | $150.64M | $108.01M | $58.29M | $33.52M | — | |
| $593.26M | $553.55M | $557M | $533.38M | $478.58M | $389.26M | $374.48M | $312.7M | — | — | — | — | — | — | — | $14.83K | |
| -$57.07M | -$62.82M | -$323.83M | -$388.14M | -$266.57M | -$161.77M | -$176.16M | -$137.36M | -$80.04M | -$53.79M | -$58.21M | -$50.75M | -$79.81M | -$58.29M | — | — | |
| — | -12.8% | -138.88% | -267.24% | -125.73% | -71.11% | -88.83% | -78.34% | -48.73% | — | — | — | — | — | — | — | |
| — | -$2.08M | -$280.27M | -$349.61M | -$233.49M | -$135.15M | -$151.58M | -$116.95M | -$61.37M | -$35.99M | -$42.08M | -$37.36M | -$74.41M | -$57.95M | — | — | |
| $10.19M | $10.75M | $11.18M | $11.3M | $11.3M | $20.1M | $19.05M | $18.83M | $9.81M | $1.2M | $800K | $7.7M | $7.43M | $130.36K | $105.92K | — | |
| $11.51M | $12.72M | $17.82M | $21.77M | $6.28M | $1.99M | $5M | $10.06M | — | — | — | — | — | — | — | — | |
| $12.26M | $13.55M | $3.32M | $12.03M | -$11.6M | -$17.92M | -$12.63M | -$9.09M | -$21.83M | -$4.57M | $632K | $156.22M | -$33.59M | -$9.87M | — | — | |
| -$44.81M | -$49.27M | -$320.51M | -$376.11M | -$278.17M | -$179.68M | -$188.79M | -$146.45M | -$101.87M | -$58.36M | -$57.58M | $105.47M | -$113.4M | -$68.16M | — | — | |
| $829K | $988K | $120K | $223K | $313K | $409K | -$19.36M | -$21K | $811K | $1.37M | -$9.68M | -$11.77M | -$2.46M | $75.78K | — | — | |
| -$21.42M | -$25.55M | -$321.55M | -$111.4M | -$278.48M | -$180.09M | -$169.43M | -$146.43M | -$102.68M | -$59.73M | -$47.9M | $117.24M | -$110.94M | -$68.24M | -$33.61M | -$14.83K | |
| — | -5.21% | -137.9% | -76.7% | -131.35% | -79.16% | -85.43% | -83.51% | -62.51% | — | — | — | — | — | — | — | |
| -$21.42M | -$25.55M | -$321.55M | -$111.4M | -$278.48M | -$180.09M | — | — | — | — | — | — | — | — | — | — | |
| -$21.64M | -$26.66M | -$320.17M | -$109.95M | -$280.83M | -$179.75M | -$171.06M | -$144.17M | -$103.19M | -$60.26M | -$47.71M | $112.27M | -$106.54M | -$68.35M | — | — | |
| USD/shares | — | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 | — | — | -$2.54 | -$1.54 | -$1.29 | $3.49 | -$1.10 | — | — | — |
| USD/shares | — | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 | — | — | -$2.54 | -$1.54 | -$1.29 | $3.17 | -$1.10 | — | — | — |
| shares | — | 89.21M | 78.89M | 74.27M | 63.76M | 59.83M | 47.54M | 42.34M | 40.43M | 38.77M | 37M | 33.56M | 25.06M | 14.21M | 3.66M | 106.68K |
| shares | — | 89.21M | 78.89M | 74.27M | 63.76M | 59.83M | 47.54M | 42.34M | 40.43M | 38.77M | 38.29M | 37.58M | 25.06M | 14.21M | 3.66M | 106.68K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2016: $2.26M in buybacks.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | $490,728,000 | $233,175,000 | $145,238,000 | $109,460,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product | $410,460,000 | $226,707,000 | — | $97,970,000 | $115,122,000 | $198,321,000 | $175,338,000 | — |
| FILSPARI | $322,005,000 | $132,222,000 | $29,208,000 | $0 | $0 | — | — | — |
| Tiopronin Products | $88,455,000 | $94,485,000 | $98,329,000 | $97,970,000 | $115,122,000 | $108,883,000 | — | — |
| License | $80,268,000 | $6,468,000 | — | $11,490,000 | $16,714,000 | $0 | $0 | — |
| Bile Acid Products | — | — | — | — | $95,654,000 | $89,438,000 | $79,700,000 | $75,070,000 |
| Thiola License | — | — | — | — | — | — | $95,638,000 | — |
| Tiopronin Products | — | — | — | — | $115,122,000 | $108,883,000 | $95,638,000 | $89,176,000 |
| Active Pharmaceutical Ingredient | — | — | $3,300,000 | — | — | — | — | — |
| Bile Acid Products | — | — | — | $102,558,000 | $95,654,000 | $89,438,000 | — | — |
| Clinical Development Activity | — | — | $14,400,000 | — | — | — | — | — |